文献速递肿瘤 PET/CT核素与放射性配体治疗

DATA混合螯合剂实现⁶⁸Ga放射性药物的即用型药盒法制备:[⁶⁸Ga]Ga-DATA-TOC的临床转化

Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC.
PubMed 文献 · EJNMMI Res · 2019-05-23

该研究报告了新型双功能DATA螯合剂偶联奥曲肽(TOC)的放射性药物前体DATA-TOC,可在室温、10分钟内以>95%标记效率完成⁶⁸Ga标记,摩尔活度最高达35 MBq/nmol。体外结合实验显示[natGa]Ga-DATA-TOC与[natGa]Ga-DOTA-TOC对hSST2亲和力相似,IC50差异仅亚纳摩尔级。小鼠及一例分化良好的NET患者直接比较中,[⁶⁸Ga]Ga-DATA-TOC肿瘤摄取与[⁶⁸Ga]Ga-DOTA-TOC相似或更优,患者肿瘤/肝脏对比度更高。

要点

  • DATA-TOC可在室温下10分钟内完成⁶⁸Ga标记,标记效率>95%,摩尔活度最高35 MBq/nmol。
  • DATA-TOC与DOTA-TOC对hSST2亲和力相似,IC50差异仅亚纳摩尔级。
  • 首例NET患者中[⁶⁸Ga]Ga-DATA-TOC肿瘤/肝脏对比度高于[⁶⁸Ga]Ga-DOTA-TOC。

核心结论

  • [⁶⁸Ga]Ga-DATA-TOC可通过高效药盒型工艺制备至适合体内使用的质量,在所有临床前测试中与[⁶⁸Ga]Ga-DOTA-TOC相当或更优,并在NET患者中实现更高的肿瘤/肝脏对比度。
  • DATA螯合剂有潜力促进⁶⁸Ga放射性药物在常规临床放射性药房环境中的获取与制备。

研究设计与样本

  • 研究合成DATA-TOC前体,并用于络合natGa(III)和⁶⁸Ga(III)。
  • 在稳定表达hSST2、hSST3或hSST5的HEK293细胞膜中,用[¹²⁵I-Tyr²⁵]LTT-SS28进行[natGa]Ga-DATA-TOC与[natGa]Ga-DOTA-TOC的竞争结合实验。
  • 在荷SST2阳性MPC-mCherry肿瘤的雌性NMRI裸鼠中进行首次体内研究,比较[⁶⁸Ga]Ga-DATA-TOC与[⁶⁸Ga]Ga-DOTA-TOC的SST2特异性肿瘤靶向及药代动力学。
  • 在一例46岁男性分化良好的NET患者中直接比较[⁶⁸Ga]Ga-DATA-TOC与[⁶⁸Ga]Ga-DOTA-TOC,为[⁶⁸Ga]Ga-DATA-TOC首次人体给药。

主要发现

  • DATA-TOC在环境温度下不到10分钟内即可完成⁶⁸Ga标记,放射化学标记效率>95%,摩尔活度最高达35 MBq/nmol。
  • [natGa]Ga-DATA-TOC与[natGa]Ga-DOTA-TOC的hSST2亲和力相似,各自IC50值差异仅为亚纳摩尔级。
  • 小鼠中[⁶⁸Ga]Ga-DATA-TOC可显示肿瘤病灶,标准化摄取值(SUV)与[⁶⁸Ga]Ga-DOTA-TOC相似。
  • NET患者中两种示踪剂的肿瘤摄取非常相似,但[⁶⁸Ga]Ga-DATA-TOC的肿瘤/肝脏对比度更高。

临床怎么用

  • DATA-TOC药盒型工艺可在室温下快速完成⁶⁸Ga标记,适合常规临床放射性药房的便捷制备。
  • [⁶⁸Ga]Ga-DATA-TOC在NET患者中肿瘤摄取与[⁶⁸Ga]Ga-DOTA-TOC相似,且肿瘤/肝脏对比度更高,提示其用于SSTR2表达肿瘤PET成像的转化潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The widespread use of 68Ga for positron emission tomography (PET) relies on the development of radiopharmaceutical precursors that can be radiolabelled and dispensed in a simple, quick, and convenient manner. The DATA (6-amino-1,4-diazapine-triacetate) scaffold represents a novel hybrid chelator architecture possessing both cyclic and acyclic character that may allow for facile access to 68Ga-labelled tracers in the clinic. We report the first bifunctional DATA chelator conjugated to [Tyr3]octreotide (TOC), a somatostatin subtype 2 receptor (SST2)-targeting vector for imaging and functional characterisation of SSTR2 expressing tumours. METHODS: The radiopharmaceutical precursor, DATA-TOC, was synthesised as previously described and used to complex natGa(III) and 68Ga(III). Competition binding assays of [natGa]Ga-DATA-TOC or [natGa]Ga-DOTA-TOC against [125I-Tyr25]LTT-SS28 were conducted in membranes of HEK293 cells transfected to stably express one of the hSST2,3,5 receptor subtypes (HEK293-hSST2/3/5 cells). First in vivo studies were performed in female NMRI-nude mice bearing SST2-positive mouse phaeochromocytoma mCherry (MPC-mCherry) tumours to compare the in vivo SST2-specific tumour-targeting of [68Ga]Ga-DATA-TOC and its overall pharmacokinetics versus the [68Ga]Ga-DOTA-TOC reference. A direct comparison of [68Ga]Ga-DATA-TOC with the well-established PET radiotracer [68Ga]Ga-DOTA-TOC was additionally performed in a 46-year-old male patient with a well-differentiated NET (neuroendocrine tumour), representing the first in human administration of [68Ga]Ga-DATA-TOC. RESULTS: DATA-TOC was labelled with 68Ga with a radiolabelling efficiency of > 95% in less than 10 min at ambient temperature. A molar activity up to 35 MBq/nmol was achieved. The hSST2-affinities of [natGa]Ga-DATA-TOC and [natGa]Ga-DOTA-TOC were found similar with only sub-nanomolar differences in the respective IC50 values. In mice, [68Ga]Ga-DATA-TOC was able to visualise the tumour lesions, showing standardised uptake values (SUVs) similar to [68Ga]Ga-DOTA-TOC. Direct comparison of the two PET tracers in a NET patient revealed very similar tumour uptake for the two 68Ga-radiotracers, but with a higher tumour-to-liver contrast for [68Ga]Ga-DATA-TOC. CONCLUSION: [68Ga]Ga-DATA-TOC was prepared, to a quality appropriate for in vivo use, following a highly efficient kit type process. Furthermore, the novel radiopharmaceutical was comparable or better than [68Ga]Ga-DOTA-TOC in all preclinical tests, achieving a higher tumour-to-liver contrast in a NET-patient. The results illustrate the potential of the DATA-chelator to facilitate the access to and preparation of 68Ga-radiotracers in a routine clinical radiopharmacy setting.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Sinnes JP, Nagel J, Waldron BP, et al. Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC. EJNMMI Res. 2019. PMID: 31123943. doi:10.1186/s13550-019-0516-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。